Novacyt SA Ownership

Pink Sheets USA . 
Stock . Novacyt SA
NVYTF Stock  USD 0.70  0.13  22.81%   
Novacyt SA maintains a total of 70.63 Million outstanding shares. Novacyt SA secures 3.49 % of its outstanding shares held by insiders and 1.6 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in pink sheets such as Novacyt SA in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Novacyt SA, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novacyt SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Novacyt Pink Sheet Ownership Analysis

The company has price-to-book ratio of 0.4. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Novacyt SA recorded a loss per share of 0.17. The entity had not issued any dividends in recent years. The firm had 15:1 split on the 28th of June 2012. Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Vlizy-Villacoublay, France. Novacyt operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 210 people.The quote for Novacyt SA is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Novacyt SA contact the company at 33 1 39 46 51 04 or learn more at https://www.novacyt.com.

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in Novacyt Pink Sheet

Novacyt SA financial ratios help investors to determine whether Novacyt Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novacyt with respect to the benefits of owning Novacyt SA security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY